Methods for collecting and using placenta cord blood stem cells

• US 9,364,585 B2
• Filed: 12/10/2012
• Issued: 06/14/2016
• Est. Priority Date: 05/11/2006
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Takabe, Naoko
• Primary Examiner(s): Noble, Marcia S
• Application Number:
  US13/709,815
• Publication Number:
  US 20130108591A1
• Time in Patent Office: 1,282 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Claims

1. A method for treating a mammal comprising a damaged tissue, comprising:

a) providing isolated cord blood stem cells by;

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells; and

b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of the isolated cord blood stem cells and cells derived therefrom, whereby the damaged tissue is treated.

2. A method according to claim 1, wherein said introducing comprises:

introducing into the mammal a composition comprising a therapeutically effective amount of the isolated cord blood stem cells.

3. A method according to claim 1, wherein said introducing comprises:

obtaining said cells derived therefrom by culturing in vitro the isolated cord blood stem cells, thereby producing said cells derived therefrom; and

introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived therefrom.

4. The method according to claim 3, wherein said cells derived therefrom are expanded stem cells.

5. The method according to claim 1, wherein said introducing comprises introducing into the mammal intravenously or by direct injection into the damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of isolated cord blood stem cells and cells derived therefrom.

6. The method according to claim 5, wherein the tissue comprises one or more of cardiac tissue, muscle tissue, liver, skin, neural tissue, bone tissue, epithelia, stroma, or endothelium.

7. A method for treating a mammal comprising a damaged tissue, comprising:

(a) optionally culturing in vitro isolated cord blood stem cells, thereby producing expanded stem cells, said isolated cord blood stem cells being obtained by;

i) performing machine perfusion of an isolated mammalian placenta comprising cord blood comprising cord blood stem cells,

said performing machine perfusion being done with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells,

wherein said isolated mammalian placenta is non-exsanguinated;

ii) collecting the perfusate; and

iii) isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells; and

(b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells selected from the group consisting of;

i) said isolated cord blood stem cells;

ii) said expanded stem cells, and

iii) combinations thereof;

whereby said damaged tissue is treated.

8. A method for treating a mammal comprising a damaged tissue, comprising:

a) providing isolated cord blood stem cells by;

i) providing an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is partially exsanguinated to produce a volume of cord blood comprising a first population of isolated cord blood stem cells;

ii) conducting machine perfusion of the isolated mammalian placenta with a pressure mediated flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said machine perfusion is performed using a pump;

iii) collecting the perfusate; and

iv) isolating the cord blood stem cells from the perfusate to produce a second population of isolated cord blood stem cells;

wherein said second population of isolated cord blood stem cells has a greater percentage of CD 133+ cells than said first population of isolated cord blood stem cells; and

b) introducing into a mammal comprising a damaged tissue a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells or cells derived from the second population of isolated cord blood stem cells, whereby the damaged tissue is treated.

9. A method according to claim 8, wherein said introducing comprises:

introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells.

10. A method according to claim 8, wherein said introducing comprises:

obtaining said cells derived therefrom by culturing in vitro cells from the second population of isolated cord blood stem cells, thereby producing said cells derived from the second population of isolated cord blood stem cells; and

introducing into the mammal a composition comprising a therapeutically effective amount of said cells derived from the second population of isolated cord blood stem cells.

11. A method according to claim 8, wherein said introducing comprises introducing into the mammal a composition comprising a therapeutically effective amount of cells from the second population of isolated cord blood stem cells, said composition further comprising cells from the first population of isolated cord blood stem cells.